Urinary incontinence remains a significant post-prostatectomy sequalae. While many patient and technical factors have been found to contribute to post-prostatectomy incontinence, the impact of anatomical differences by races has not been studied .
To evaluate the safety and efficacy of the eCoin® – a nickel-sized, primary battery-powered, neuromodulation device for the treatment of urgency urinary incontinence which is implanted in the lower leg in a 20-minute procedure under local anesthesia.
The aim of this study is to describe the prevalence and type of female voiding dysfunction (FVD) in patients with overactive bladder (OAB) who were studied by urodynamics and its relationship with voiding symptoms.
This study describes patients with different degrees and combinations of symptom resolution in response to fesoterodine exposure to aid physicians in counselling patients with overactive bladder (OAB) on the likelihood of treatment success.
To investigate the association of nocturia with the prevalence of cardiovascular disease (CVD) using the National Health and Nutrition Examination Survey (NHANES) data. Among the 40 790 individuals who participated in NHANES from 2005 to 2012, 14 114 adults were analyzed in this study.
Infants with myelomeningocele are at risk for chronic kidney disease caused by neurogenic bladder dysfunction. Urodynamic evaluation plays a key role to risk stratify individuals for renal deterioration.
Charles Ryan: Hi, Chuck Ryan here from the University of Minnesota. Joining me today is Dr. Michael Morris, a Medical Oncologist and a Professor at Weill Cornell and Prostate Cancer Section Head and full member at Memorial Sloan Kettering Cancer Center in New York City. Dr. Morris is one of the lead investigators on the […]
{{header-clinical-trials-navigation}} TALAPRO-3: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER Condition: Prostate Cancer Study Type: Interventional Clinical Trials Identifier NCT 8-digits: NCT04821622 Sponsor: Pfizer Phase: Phase 3 Eligibility: Age: minimum 18 Years maximum N/A Gender: Male Inclusion Criteria: 1. […]
{{header-clinical-trials-navigation}} A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Darolutamide in Addition to Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Men With Metastatic Hormone-sensitive Prostate Cancer (mHSPC) Condition: Prostatic Neoplasms Study Type: Interventional Clinical Trials Identifier NCT 8-digits: NCT04736199 Sponsor: Bayer Phase: Phase 3 Eligibility: Age: minimum 18 Years maximum N/A Gender: Male […]
{{header-clinical-trials-navigation}} Patients’ Preferences in the Treatment of Hormone-sensitive Metastatic Prostate Cancer: a Discrete Choice Experiment Condition: Prostate Cancer Metastatic, Radiotherapy Side Effect, Surgery, Urologic Cancer, Quality of Life, Patient Satisfaction, Health Care Utilization Study Type: Observational Clinical Trials Identifier NCT 8-digits: NCT04590976 Sponsor: Imperial College London Phase: Eligibility: Age: minimum 18 Years maximum N/A Gender: […]
